ClinicalTrials.gg
CompletedNCT01444846Updated Jun 3, 2026Results posted

Otoprotection With SPI-1005 for Prevention of Temporary Auditory Threshold Shift

A Phase 2 interventional study of SPI-1005 Low dose and SPI-1005 Middle dose in Temporary Auditory Threshold Shift, sponsored by Sound Pharmaceuticals, Incorporated. Completed at 1 site in United States. Open to participants aged 18 Years to 31 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-03.

Sponsored by Sound Pharmaceuticals, Incorporated · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
83
Allocation
Randomized
Ages
18 Years to 31 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 321 studies in Hearing Loss with a site in United States — 82 open to participants now, 94 under way, 3 of them phase 3. Hearing Loss · United States.

Enrollment
95th of 272
83 · median 48
Started
2011
with 5 others
Phase 2
20 of 321
5 open now
Registered
53rd of 321
by date
Lead sponsor
9 of 321
Sound Pharmaceuticals, Incorporated

Among the 321 studies in Hearing Loss with a site in United States, this one is the 95th largest by enrollment of the 272 interventional ones that give a count, is one of 6 that started in 2011, is one of 20 in phase 2, and was the 53rd registered.

Hearing Loss

796 studies on the registry are indexed under Hearing Loss; 194 are open to participants now.

Browse Hearing Loss studies →

Open to participants now

82 of the 321 studies in Hearing Loss with a site in United States are open now. Recruiting first, the newest first:

77 more — sign in →

All 82 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 124 Hearing Loss studies recruiting now, 60 (48%) set no upper age limit and 42 (34%) stop at 75 or younger; 46 take children under 18; 46 take healthy volunteers.

This study: 18 Years to 31 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 321 studies in Hearing Loss with a site in United States, or all of them as a file.
02

Study summary

Exposure to loud sounds can cause hearing loss. The purpose of this research study is to evaluate potential prevention of temporary changes in hearing that may occur after listening to music through an iPod or personal music player. We will measure temporary changes in hearing in subjects who listen to music and take either the study drug, SPI-1005, or a placebo for 4 days. SPI-1005 is a proprietary preparation of ebselen that allows it to be taken by mouth. Ebselen contains the mineral selenium and behaves like Glutathione Peroxidase, an enzyme that helps to rid the body of damaging chemicals caused by loud sounds.

Read the detailed description

The objective of this study was to determine the safety and efficacy of SPI-1005 in the prevention of sensorineural hearing loss or temporary auditory threshold shift (TTS) using pure tone audiometry. Subjects with normal to slight hearing loss were screened on clinic visit day 1 (CV1) and after satisfying specific otologic inclusion and exclusion criteria, were enrolled and randomized to either SPI-1000 (placebo) or one of three doses of ebselen (SPI-1005): 200, 400 or 600 mg. Subjects began taking placebo or SPI-1005 by mouth for four days beginning two days prior to CV2. On CV2 subjects had their blood drawn for peak/trough analysis of ebselen and metabolites and their baseline hearing thresholds determined by audiometry. Subjects were then exposed to 100 decibels (dBA) of sound delivered from a calibrated iPod® via insert earphones for 4 continuous hours. Subjects had their hearing serially tested at 4 additional times post-noise exposure on the same day to determine their threshold shift. Subjects returned to clinic 24 hours later on CV3 and 7 days later on CV4 for additional safety and efficacy assessments including repeat audiometry. Efficacy was determined by comparing the threshold shift in an SPI-1005 treated group vs placebo.

Exposure to SPI-1005 (ebselen and the major and minor metabolites) was quantified from plasma by LC-MS/MS. The plasma values from the peak/trough sampling were taken before and after the 5th oral dose on Clinic Visit 2 (CV2) when subjects were expected to be at steady-state. Plasma selenium levels were quantified by ICP-MS prior to dosing at CV1, at CV2 during peak/trough sampling for ebselen and metabolites, and at CV4 or 5 days after the last scheduled dose.

The multi-dose safety of SPI-1005 was determined by repeated History \& Physical examinations, serology (Chemistry Panel-20), hematology (CBC with differential), and radiology (chest x-rays). Safety was determined by comparing the changes in laboratory values in SPI-1005 groups vs placebo.

03

Conditions studied

  • Temporary Auditory Threshold Shift

Keywords

  • Temporary Auditory Threshold Shift
  • Hearing Loss
  • Deafness
  • SPI-1005
  • Ebselen
04

Who can participate

Ages eligible
18 Years to 31 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy subjects at the time of enrollment.
  • Each subject will give to participate in this study and agrees to the treatment protocol.
  • Each subject will be interviewed regarding hearing and health to reveal any history of hearing loss, tinnitus, known ear pathology, use of any potentially ototoxic medications (i.e. diuretics, minocycline).
  • Non-occupational sound exposure (e.g., concerts, firearms, fireworks, power tools) will be avoided during the 24-hour period preceding baseline testing and throughout the duration of the study.
  • Subjects will have vital signs (i.e., heart rate, blood pressure, respirations, temperature) within normal limits upon medical examination.
  • Subjects must have normal audiologic assessment at baseline consisting of:
  • Baseline audiometric evaluation confirms that subjects have symmetric hearing with air conduction thresholds no worse than 25 decibels of Hearing Loss (dBHL) at frequencies between 0.25 to 8 kilo Hertz (kHz) bilaterally.
  • No significant threshold asymmetry (i.e. greater than 15 dB) between the ears at any tested frequency.
  • No significant air-bone gaps (i.e. greater than 10 dB)
  • Type A tympanograms bilaterally, defined as a range of -140 to +40 dekaPascals (daPa) based on the 90% range for adults (Margolis and Hunter 2000)

Exclusion criteria

Exclusion Criteria:

    • Subjects with abnormal hearing levels > 25 dBHL at any tested frequency (250, 500, 1000, 2000, 3000, 4000, 6000 and 8000 Hz) for either ear.
  • Exposure to any duration of non-occupational high-level sound (e.g., concerts, firearms, fireworks, power tools) during the 24 hour period preceding baseline audiometric testing as revealed in the subject questionnaire or during the medical examination.
  • Pathology of the external ear discovered upon otoscopic examination.
  • Pathology of the middle ear revealed by otoscopic examination, abnormal tympanometry, or reported history of middle ear problems.
  • Pathology of the inner ear or auditory nerve as revealed by reported history.
  • Subject complaints of aural pain, pressure, fullness, or drainage.
  • Subjects testing positive for pregnancy will be excluded from the study.
  • Subjects with other medical/health issues that would preclude voluntary participation in a drug study may be excluded at the discretion of the Principal Investigator.
  • Subjects that have previously received any known potentially ototoxic medication. This includes, but is not limited to, high dose salicylates (>2 g/day), platinum-based chemotherapeutics and aminoglycoside antibiotics, such as streptomycin, gentamicin,tobramycin, amikacin, neomycin, and netilmycin.
  • Subjects that are currently using of any potentially ototoxic medications (i.e. diuretics or minocycline).
  • Subjects that have received any treatment (drug or device) in the six months prior to this study.
  • Subjects exhibiting or self-reporting shortness of breath, wheezing, coughing, or hemoptysis
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
83 participants (actual)

Study arms

  • Active comparator
    SPI-1005 Low dose

    200mg SPI-1005, capsule, bid, po, x4d

    Drug: SPI-1005 Low dose

  • Active comparator
    SPI-1005 Middle Dose

    400mg SPI-1005, capsule, bid, po, x4d

    Drug: SPI-1005 Middle dose

  • Active comparator
    SPI-1005 High Dose

    600mg SPI-1005, capsule, bid, po, x4d

    Drug: SPI-1005 High dose

  • Placebo comparator
    Placebo

    0mg SPI-1005, capsule, bid, po, x4d

    Drug: Placebo

Interventions

  • Oral capsules, 200 mg ebselen, twice daily, 4 days

    Also known as: 200 mg Ebselen

  • DrugSPI-1005 Middle dose

    Oral capsules, 400 mg ebselen, twice daily, 4 days

    Also known as: 400 mg Ebselen

  • Oral capsules, 600 mg ebselen, twice daily, 4 days

    Also known as: 600mgEbselen

  • DrugPlacebo

    Oral capsules, 0 mg ebselen, twice daily, 4 days

    Also known as: 0 mg Ebselen

06

What researchers measure

Primary outcomes

  1. Change in Temporary Threshold Shift at 4 kHz--Intent To Treat (ITT) Population

    The primary efficacy analysis was change in air conduction threshold at 4 kHz collected in the ITT Population on the day of sound exposure. Baseline hearing thresholds were collected on Clinic Visit 2 prior to sound exposure and used in calculating the primary efficacy endpoints. Hearing thresholds after sound exposure were collected and compared to baseline threshold to calculate change from baseline. Threshold changes from baseline were determined for each ear, frequency, and post sound time point, then analyzed by Mixed-effects Model Repeated Measures (MMRM) methods using triply repeated measurements for each subject. The MMRM had fixed effects for treatment, ear, frequency, and time, all 2-way interactions and the 3-way interaction treatment by-frequency-by-time plus a random effect for subject nested within treatment.

    Time frame: 15 minutes post Controlled Sound Challenge

  2. Change in Temporary Threshold Shift at 4 kHz--Per Protocol (PP) Population

    The primary efficacy analysis was change in air conduction threshold at 4 kHz collected in the PP Population on the day of sound exposure. Baseline hearing thresholds were collected on Clinic Visit 2 prior to sound exposure and used in calculating the primary efficacy endpoints. Hearing thresholds after sound exposure were collected and compared to baseline threshold to calculate change from baseline. Threshold changes from baseline were determined for each ear, frequency, and post sound time point, then analyzed by Mixed-effects Model Repeated Measures (MMRM) methods using triply repeated measurements for each subject. The MMRM had fixed effects for treatment, ear, frequency, and time, all 2-way interactions and the 3-way interaction treatment by-frequency-by-time plus a random effect for subject nested within treatment.

    Time frame: 15 minutes post Controlled Sound Challenge

07

Results

Posted Jun 3, 2026
Limitations and caveats
The primary limitations of this study are small sample size and results from a single center. The data collected is supportive of continued evaluation of SPI-1005 for prevention of Temporary Auditory Threshold shift in larger multi-center trials.

Participant flow

Participant flow — Overall Study
MilestoneSPI-1005 Low DoseSPI-1005 Middle DoseSPI-1005 High DosePlacebo
Started22202120
Completed20202119
Not completed2001

Outcome measures

PrimaryChange in Temporary Threshold Shift at 4 kHz--Intent To Treat (ITT) Population

The primary efficacy analysis was change in air conduction threshold at 4 kHz collected in the ITT Population on the day of sound exposure. Baseline hearing thresholds were collected on Clinic Visit 2 prior to sound exposure and used in calculating the primary efficacy endpoints. Hearing thresholds after sound exposure were collected and compared to baseline threshold to calculate change from baseline. Threshold changes from baseline were determined for each ear, frequency, and post sound time point, then analyzed by Mixed-effects Model Repeated Measures (MMRM) methods using triply repeated measurements for each subject. The MMRM had fixed effects for treatment, ear, frequency, and time, all 2-way interactions and the 3-way interaction treatment by-frequency-by-time plus a random effect for subject nested within treatment.

Time frame:
15 minutes post Controlled Sound Challenge
Reported as:
Mean · dbHL
Change in Temporary Threshold Shift at 4 kHz--Intent To Treat (ITT) Population
dbHLSPI-1005 Low DoseSPI-1005 Middle DoseSPI-1005 High DosePlacebo
Change in Temporary Threshold Shift at 4 kHz--Intent To Treat (ITT) Population3.23 (1.97 to 4.49)1.32 (0.06 to 2.58)3.81 (2.57 to 5.04)4.07 (2.81 to 5.34)
Statistical analysis
  • SPI-1005 Low Dose vs SPI-1005 Middle Dose vs SPI-1005 High Dose vs Placebo · Mixed Models Analysis · p = <0.05 (Analysis strategy for air conduction thresholds used a Linear Mixed Model (LMM) with correlations among from the same subject. Model fitting process for each Mixed Effects model Repeat Measurements (MMRM) analyses performed for study are reported.)
  • SPI-1005 Low Dose vs SPI-1005 Middle Dose vs SPI-1005 High Dose vs Placebo · Mixed Models Analysis · p = <0.05 (Multiple comparisons were made using the Mixed effects Multiple Repeated Measures model.)
PrimaryChange in Temporary Threshold Shift at 4 kHz--Per Protocol (PP) Population

The primary efficacy analysis was change in air conduction threshold at 4 kHz collected in the PP Population on the day of sound exposure. Baseline hearing thresholds were collected on Clinic Visit 2 prior to sound exposure and used in calculating the primary efficacy endpoints. Hearing thresholds after sound exposure were collected and compared to baseline threshold to calculate change from baseline. Threshold changes from baseline were determined for each ear, frequency, and post sound time point, then analyzed by Mixed-effects Model Repeated Measures (MMRM) methods using triply repeated measurements for each subject. The MMRM had fixed effects for treatment, ear, frequency, and time, all 2-way interactions and the 3-way interaction treatment by-frequency-by-time plus a random effect for subject nested within treatment.

Time frame:
15 minutes post Controlled Sound Challenge
Reported as:
Mean · dB HL
Change in Temporary Threshold Shift at 4 kHz--Per Protocol (PP) Population
dB HLSPI-1005 Low DoseSPI-1005 Middle DoseSPI-1005 High DosePlacebo
Change in Temporary Threshold Shift at 4 kHz--Per Protocol (PP) Population3.35 (2.07 to 4.64)1.30 (0.05 to 2.55)3.69 (2.37 to 5.01)4.09 (2.84 to 5.35)
Statistical analysis
  • SPI-1005 Low Dose vs SPI-1005 Middle Dose vs SPI-1005 High Dose vs Placebo · Mixed Models Analysis · p = <0.05 (Analysis strategy for air conduction thresholds used a Linear Mixed Model (LMM) with correlations among from the same subject. Model fitting process for each Mixed Effects model Repeat Measurements (MMRM) analyses performed for study are reported.)
  • SPI-1005 Low Dose vs SPI-1005 Middle Dose vs SPI-1005 High Dose vs Placebo · Mixed Models Analysis · p = <0.05 (Multiple comparisons were made using the Mixed effects Multiple Repeated Measures model.)

Adverse events

Collected over AEs were collected over a period of roughly 1 year.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SPI-1005 Low Dose—0/22 (0%)3/22 (13.6%)
SPI-1005 Middle Dose—0/20 (0%)5/20 (25%)
SPI-1005 High Dose—0/21 (0%)4/21 (19%)
Placebo—0/20 (0%)2/20 (10%)
Most frequent other events
Showing 10 of 15
Most frequent other events
EventSPI-1005 Low DoseSPI-1005 Middle DoseSPI-1005 High DosePlacebo
CoughRespiratory, thoracic and mediastinal disorders0/220/202/210/20
Abdominal DiscomfortGastrointestinal disorders0/220/201/211/20
Abdominal pain upperGastrointestinal disorders0/221/200/210/20
Procedural dizzinessInjury, poisoning and procedural complications1/221/200/210/20
SunburnInjury, poisoning and procedural complications0/221/200/210/20
Blood alkaline phosphatase increasedInvestigations0/220/201/211/20
Blood phosphorus increasedInvestigations0/220/200/211/20
HeadacheNervous system disorders0/221/200/210/20
Rhinitis allergicRespiratory, thoracic and mediastinal disorders0/221/200/210/20
Hot flushVascular disorders0/221/200/210/20

Baseline characteristics

The study design included subjects with normal to slight hearing loss. Normal hearing is defined as having a baseline threshold of -10 dB to 15 dB at one or more tested frequencies. Slight hearing loss is defined as having baseline thresholds greater than 15 dB HL and up to 25 dB HL at one or more tested frequencies.

Age, Customized
Age, Customized(years)SPI-1005 Low DoseSPI-1005 Middle DoseSPI-1005 High DosePlaceboTotal
Median21.0 (19 to 25)20.0 (19 to 23)20.0 (18 to 21)21.0 (18 to 26)20.0 (18 to 26)
Sex: Female, Male
Sex: Female, Male(Participants)SPI-1005 Low DoseSPI-1005 Middle DoseSPI-1005 High DosePlaceboTotal
Female1011141348
Male1297735
Region of Enrollment
Region of Enrollment(participants)SPI-1005 Low DoseSPI-1005 Middle DoseSPI-1005 High DosePlaceboTotal
United States2220212083
08

Study locations

1 site
  • University of Florida
    Gainesville, Florida 32610, United States
09

References and documents

Publications

  • Pourbakht A, Yamasoba T. Ebselen attenuates cochlear damage caused by acoustic trauma. Hear Res. 2003 Jul;181(1-2):100-8. doi: 10.1016/s0378-5955(03)00178-3. PubMed 12855368 ↗
  • Lynch ED, Gu R, Pierce C, Kil J. Ebselen-mediated protection from single and repeated noise exposure in rat. Laryngoscope. 2004 Feb;114(2):333-7. doi: 10.1097/00005537-200402000-00029. PubMed 14755214 ↗
  • Lynch ED, Gu R, Pierce C, Kil J. Reduction of acute cisplatin ototoxicity and nephrotoxicity in rats by oral administration of allopurinol and ebselen. Hear Res. 2005 Mar;201(1-2):81-9. doi: 10.1016/j.heares.2004.08.002. PubMed 15721563 ↗
  • Yamasoba T, Pourbakht A, Sakamoto T, Suzuki M. Ebselen prevents noise-induced excitotoxicity and temporary threshold shift. Neurosci Lett. 2005 Jun 3;380(3):234-8. doi: 10.1016/j.neulet.2005.01.047. Epub 2005 Feb 1. PubMed 15862892 ↗
  • Lynch ED, Kil J. Compounds for the prevention and treatment of noise-induced hearing loss. Drug Discov Today. 2005 Oct 1;10(19):1291-8. doi: 10.1016/S1359-6446(05)03561-0. PubMed 16214673 ↗
  • Kil J, Pierce C, Tran H, Gu R, Lynch ED. Ebselen treatment reduces noise induced hearing loss via the mimicry and induction of glutathione peroxidase. Hear Res. 2007 Apr;226(1-2):44-51. doi: 10.1016/j.heares.2006.08.006. Epub 2006 Oct 6. PubMed 17030476 ↗
  • Lynch E, Kil J. Development of Ebselen, a Glutathione Peroxidase Mimic, for the Prevention and Treatment of Noise-Induced Hearing Loss. Semin Hear 2009; 30(1): 047-055
  • Le Prell CG, Yang Q, Harris JG. Modification of digital music files for use in human temporary threshold shift studies. J Acoust Soc Am. 2011 Oct;130(4):EL142-6. doi: 10.1121/1.3630017. PubMed 21974483 ↗
  • Le Prell CG, Dell S, Hensley B, Hall JW 3rd, Campbell KC, Antonelli PJ, Green GE, Miller JM, Guire K. Digital music exposure reliably induces temporary threshold shift in normal-hearing human subjects. Ear Hear. 2012 Nov-Dec;33(6):e44-58. doi: 10.1097/AUD.0b013e31825f9d89. PubMed 22885407 ↗
  • Kil J, Lobarinas E, Spankovich C, Griffiths SK, Antonelli PJ, Lynch ED, Le Prell CG. Safety and efficacy of ebselen for the prevention of noise-induced hearing loss: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2017 Sep 2;390(10098):969-979. doi: 10.1016/S0140-6736(17)31791-9. Epub 2017 Jul 14. PubMed 28716314 ↗
  • Spankovich C, Le Prell CG. Associations between dietary quality, noise, and hearing: data from the National Health and Nutrition Examination Survey, 1999-2002. Int J Audiol. 2014 Nov;53(11):796-809. doi: 10.3109/14992027.2014.921340. Epub 2014 Jun 30. PubMed 24975234 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2011, a primary completion of Dec 2013 and a completion of Mar 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2026, 12 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2011
First posted
Oct 3, 2011
Start
Sep 2011
Primary completionActual
Dec 2013
CompletionActual
Mar 2014
Results first posted
Jun 3, 2026
Last update
Jun 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01444846
Lead sponsor
Sound Pharmaceuticals, Incorporated
Responsible party
Sponsor
First posted
Oct 3, 2011
Start date
Sep 2011
Primary completion
Dec 2013
Completion
Mar 2014
Results posted
Jun 3, 2026
Last update
Jun 3, 2026

Study contacts

Colleen Le Prell, PhD
principal investigator · University of Florida
Jonathan Kil, MD
study director · Sound Pharmaceuticals, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion